SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Offer Wholly Unconditional

17 Jan 2020 07:00

RNS Number : 0961A
Open Orphan PLC
17 January 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION

 

17 January 2020

Recommended All Equity Offer

for

HVIVO PLC ("HVIVO")

to merge with

OPEN ORPHAN PLC ("OPEN ORPHAN")

 

 Offer Wholly Unconditional

Introduction

On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the "Offer"). Under the terms of the Offer, hVIVO Shareholders will be entitled to receive 2.47 New Open Orphan Shares for every one hVIVO Share. The Offer represents a value of approximately 15.56 pence per hVIVO Share and a premium of 33.8 per cent. based upon the hVIVO Closing Price on 6 December 2019, being the last practicable date prior to announcement of the Offer, valuing hVIVO at approximately £12.96 million.

On 31 December 2019, Open Orphan announced that the Offer had been declared unconditional as to acceptances and on 14 January 2020 announced that it had received acceptances in respect of 77,348,100 hVIVO Shares, representing approximately 92.5 per cent. of the issued ordinary share capital of hVIVO.

Offer Wholly Unconditional

Open Orphan announces that it has decided, in accordance with the Offer Document, to waive the outstanding conditions under the Offer. Accordingly, there are no further conditions to be satisfied and the Offer is now unconditional in all respects.

Admission of the Enlarged Share Capital

Application has been made for the admission of the Consideration Shares and the Existing Ordinary Shares, being 445,622,374 Ordinary Shares to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 20 January 2020.

Compulsory acquisition

Open Orphan intends to shortly exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares. The compulsory acquisition will be settled on the same terms as the Offer and hVIVO Shareholders will be entitled to receive 2.47 Open Orphan Shares for every 1 hVIVO Share.

In exercising such rights in respect of hVIVO Shares held by hVIVO Shareholders in, or with a registered address in, a Restricted Jurisdiction, Open Orphan may elect to arrange for such hVIVO Shares to be sold on behalf of the relevant hVIVO Shareholder and the proceeds (less the costs and expenses of such sale) remitted to such hVIVO Shareholder.

Enquiries:

 

Open Orphan plc

Cathal Friel, Chief Executive Officer

 

+353 (0)1 644 0007

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Ben Cryer

 

+44 (0)20 7614 5900

JE Davy (Euronext Adviser and Joint Broker)

Anthony Farrell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPUNUARRRUAAUR
Date   Source Headline
11th Mar 20217:00 amRNSJournal for Clinical Studies article publication
9th Mar 20217:00 amRNSNew contract win with Oxford BioTherapeutics
26th Feb 20214:58 pmRNSHolding(s) in Company
17th Feb 20219:00 amRNSEthics approval - COVID-19 Human Challenge Study
9th Feb 20213:57 pmRNSHolding(s) in Company
3rd Feb 20217:05 amRNSExercise of Investor Warrants & TVR
3rd Feb 20217:00 amRNSNew challenge study quarantine clinic
1st Feb 20217:00 amRNSContract extension with Carna Biosciences
21st Jan 20217:00 amRNSArticle published in Drug Discovery Today
20th Jan 20217:00 amRNSExpansion of volunteer recruitment centres
11th Jan 20217:00 amRNSFirst volunteer dosed in COVID-19 clinical trial
6th Jan 20214:29 pmRNSHolding(s) in Company
6th Jan 20217:00 amRNSContract renewal with top-3 pharmaceutical client
31st Dec 20207:00 amRNSRule 19.6(c) Confirmation
23rd Dec 20207:00 amRNSSuccessful completion of toxicology study
22nd Dec 20207:00 amRNSContract renewal with top-3 pharmaceutical client
14th Dec 20207:30 amRNSExercise of Share Options
14th Dec 20207:00 amRNSMHRA approval for nasal COVID-19 vaccine trial
7th Dec 20207:00 amRNSVenn Life Sciences contract wins
24th Nov 20207:00 amRNSDirectors Change
19th Nov 20207:00 amRNSCollaboration with HIC-VAC and Wellcome Trust
5th Nov 20207:00 amRNSNew £2.5m Influenza Challenge Study Contract Win
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:10 amRNSExercise of Share Options
30th Oct 20207:00 amRNSNew 2-year contract with a tier 1 German company
20th Oct 20207:00 amRNSContract Signed with UK Government
16th Oct 20208:47 amRNSStatement re further media comment
30th Sep 20207:00 amRNSInterim Results for 6 months ended 30 June 2020
28th Sep 20207:00 amRNSNew £4.3m Challenge Study Contract Win
24th Sep 20207:00 amRNSStatement re price movement and press speculation
23rd Sep 20204:41 pmRNSSecond Price Monitoring Extn
23rd Sep 20204:36 pmRNSPrice Monitoring Extension
22nd Sep 20207:30 amRNSExercise of Investor Warrants and Issue of Shares
22nd Sep 20207:00 amRNSNew Contract Win
7th Sep 20207:00 amRNShVIVO present at 2020 ERS International Congress
10th Aug 20207:00 amRNSMajor New Contract Win with Top 3 Pharma Company
4th Aug 20207:00 amRNSNew Contract Win with Carna Bioscience ("Carna")
28th Jul 20207:00 amRNSContract for COVID-19 Vaccine Trial
22nd Jul 202012:43 pmRNSResult of AGM
15th Jul 20207:00 amRNSOption to Acquire CHIMagents Limited
10th Jul 20208:00 amRNSEuronext Growth Dublin Notice
8th Jul 20207:00 amRNSUpcoming Investor Events
7th Jul 20207:10 amRNSExercise of Warrants
7th Jul 20207:00 amRNSAdditional Laboratory Services Contracts Signed
26th Jun 20201:05 pmRNSNotice of AGM
24th Jun 20207:00 amRNSResults for the year ended 31 December 2019
17th Jun 20209:33 amEQSHardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020
15th Jun 20207:00 amRNSPositive Phase I results published in The Lancet
12th Jun 20208:00 amRNSEuronext Growth Dublin Notice
11th Jun 202012:15 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.